- Conditions
- Breast Cancer
- Interventions
- Dato-DXd
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,186
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
- Interventions
- TT-00420, Nab-Paclitaxel
- Drug · Combination Product
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
- Interventions
- Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
- Diagnostic Test · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- Enzalutamide, Fulvestrant
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 101 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New York, New York • Germantown, Tennessee
- Conditions
- HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
- Interventions
- Palbociclib, T-DM1
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more
- Conditions
- Breast Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Oxaliplatin, Trastuzumab
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 11
- States / cities
- Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more
- Conditions
- Breast Cancer
- Interventions
- Temsirolimus, Neratinib
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 4
- States / cities
- Goodyear, Arizona • Los Angeles, California • New York, New York
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Durvalumab, Olaparib
- Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Interventions
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- 17B-estradiol, Letrozole, Anastrozole, Exemestane
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 3
- States / cities
- Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
- Conditions
- Metastatic Breast Cancer
- Interventions
- trastuzumab-MCC-DM1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 15
- States / cities
- Highland, California • Stockton, California • Denver, Colorado + 12 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Dovitinib, Fulvestrant, Dovitinib Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
- Conditions
- Metastatic Breast Cancer, Locally Recurrent Breast Cancer
- Interventions
- Eribulin, Balixafortide
- Drug
- Lead sponsor
- Spexis AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 28
- States / cities
- Fresno, California • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- Breast Cancer
- Interventions
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, Positron Emission Tomography, Therapeutic Conventional Surgery, Trastuzumab
- Radiation · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Neoplasms, Cancer of the Breast, Breast Cancer
- Interventions
- Gemcitabine, Trastuzumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 13
- States / cities
- Hot Springs, Arkansas • Pine Bluff, Arkansas • Redding, California + 10 more
- Conditions
- Endometrial Cancer, Carcinosarcoma
- Interventions
- ZW25
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 4
- States / cities
- Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Bevacizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Burbank, California • Glendale, California + 39 more
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Interventions
- HER-2/neu peptide vaccine, sargramostim
- Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HR+/HER2-negative Breast Cancer
- Interventions
- TOS-358, Fulvestrant, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- Totus Medicines
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
- Conditions
- Neoplasms, Breast
- Interventions
- lapatinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 8
- States / cities
- Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more